摘要
目的观察疏血通注射液联合依达拉奉治疗急性脑梗死的疗效和安全性。方法 90例急性脑梗死患者随机分为治疗组(46例)与对照组(44例),治疗组予疏血通注射液联合依达拉奉治疗,对照组予疏血通注射液治疗,观察两组患者治疗后美国国立卫生研究院卒中量表(NIHSS)评分的改善情况以及临床疗效。结果治疗组在治疗后的NIHSS评分较对照组明显降低,差异有统计学意义(P<0.05);治疗组的总有效率为87%,常规对照组为65.9%,差异有统计学意义(P<0.05)。结论疏血通注射液联合依达拉奉能够促进急性脑梗死患者的神经功能康复、减少致残率、提高疗效,且无明显不良反应。
Objective To investigate the clinical effect and safety of combining Shuxuetong injection with Edaravone in treatment of patients with acute cerebral infarction. Methods 90 patients with acute cerebral infarction were randomly divided into treatment group（46 cases）and control group（44 cases）,The treatment group received the treatment of combining Shuxuetong injection with Edaravone, while the control group was given Shuxuetong injection.The National Insitute of Health Stroke Scale（NIHSS）scores and the clinical effect were observed after treatment. Results After treatment the NIHSS scores in treatment group was significantly lower than that in control group, the differences was significant（P〈0.05）.Effective rate of treatment group was 87%,and the control group was 65.9%,the difference of the clinical effect between the two groups was significance（P〈0.05）.Conclusion Shuxuetong injection with Edaravone can promote recovery of nerve function, reduce disability rate,enhance the curative effect and there is no obvious adverse reaction.
出处
《中国实用医药》
2011年第19期25-26,共2页
China Practical Medicine
关键词
脑梗死
疏血通注射液
依达拉奉
Cerebral infarction
Shuxuetong injection
Edaravone
